期刊文献+

国产水痘减毒活疫苗在免疫损害病人中的应用 被引量:1

Application of Domestic Live Attenuated Varicella Vaccine in Immunocompromised Patients
下载PDF
导出
摘要 目的观察国产Oka株水痘减毒活疫苗在急性白血病、实体肿瘤和接受免疫抑制剂治疗的免疫损害病人中的反应原性和抗体应答。方法国产Oka株水痘减毒活疫苗接种于3种免疫损害病人,用ELISA法检测免疫前和免疫后抗体水平,并观察副反应情况。结果接种疫苗的3种病人均无异常反应发生,仅有少数病人在观察期内有中强程度发热,其中以实体肿瘤病人略多。3种病人接种前多数抗体阳性,经疫苗免疫后,抗体滴度均有不同程度上升,正在使用免疫抑制剂者抗体滴度上升不明显。结论免疫损害病人接种国产水痘减毒活疫苗是安全有效的。 Objective To observe the reactogenicity and antibody response of domestic live attenuated varicella vaccine prepared with Oka strain in the patients with acute leukemia or solid tumors or receiving immunosuppressants. Methods Immunize the above-mentioned immunocompromised patients with domestic live attenuated varicella vaccine prepared with Oka strain, determine the antibody levels before and after immunization and observe the adverse reactions. Results No abnormal reactions were observed in all the patients. Moderate or severe fever were observed in a few patients ,most of whom were those with solid tumors. Most of the patients were positive for varicella antibody before immunization, and their antibody titers increased at various degrees after immunization. However,the antibody titers of patients treated with immunosuppressants showed no significant increase. Conclusion Domestic live attenuated varicella vaccine was safe and effective in immunocompromised patients.
出处 《中国生物制品学杂志》 CAS CSCD 2007年第9期685-687,共3页 Chinese Journal of Biologicals
关键词 水痘减毒活疫苗 免疫损害 反应原性 抗体应答 Live attenuated varicella vaccine Immunocompromise Reactogenicity Antibody response
  • 相关文献

参考文献14

  • 1Hill G,Chauvenet AR,Lovato J,et al.Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia.Pediatrics,2005,116(4):e525-529.
  • 2Andre FE.Summary of clinical studies with the Oka live varicella vaccine produced by Smith Kline-RIT.Biken J,1984,27(2-3):89-98.
  • 3Andre FE.Worldwide experience with the Oka-strain live varicella vaccine.Postgrad Med J,1985,61(Suppl 4):113-120.
  • 4Kappaqoda C,Shaw P,Burqess M,et al.Varicella vaccine in non-immune household contacts of children with cancer or leukaemia.J Paediatr Child Health,1999,35(4):341-345.
  • 5Morales-Castillo ME,Alvarez-Munoz MT,Solorzano-Santos F,et al.Live varicella vaccine in both immunocompromised and healthy children.Arch Med Res,2000,31(1):85-87.
  • 6Emir S,Buyukpamukcu M,Koseoglu V,et al.Varicella vaccination in children with lymphoma and solid tumours.Postgrad Med J,2006,82(973):760-762.
  • 7Leunq TF,Li CK,Hunq EC,et al.Immunogenicity of a two-dose regime of varicella vaccine in children with cancers.Eur J Haematol,2004,72(5):353-357.
  • 8Kitai I C,King S,Gafni A.An economic evaluation of varicella vaccine for pediatric liver and kidney transplant recipients.Clin Infect Dis,1993,17(3):441-447.
  • 9Olson AD,Shope TC,Flynn JT.Pretransplant varicella vaccination is cost-effective in pediatric renal transplantation.Pediatr Transplant,2001,5(1):44-50.
  • 10Pacini-Edelstein SJ,Mehra M,Ament ME,et al.Varicella in pediatric liver transplant patients:a retrospective analysis of treatment and outcome.J Pediatr Gastroenterol Nutr,2003,37(2):183-186.

二级参考文献15

  • 1Strassels S A, Sullivan S D. Clinical and economic considerations of vaccination against vaficella[ J ]. Pharmacotherapy, 1997,17( 1 ) : 133- 139.
  • 2Diez - Domingo J, Ridao M, Latour J, et al. A Cost - benefit analysis of routine varicella vaccination in Spain[J]. Vaccine, 1999, 17( 11 -12) : 1306 - 1311.
  • 3Preblud S R, Orenstein W A, Koplan J P, et al. A benefit - cost analysis of a childhood varieella vaccination programme[J]. Postgrad Med J, 1985,61(Supp14):17 - 22.
  • 4Huse D M, Meissner H C, Lacey M J, et al.Childhood vaccination against chickenpox: an analysis of benefits and costs [J ]. J Pediatr,1994,124(6) :869 - 874.
  • 5Beutels P, Clara G, Tormans E, et al. Cost and benefit analysis of routine varicella vaccination in German Children [J]. JID, 1996, 174(Suppl 3) :335 - 341.
  • 6Brisson M, Edmunds W J. The cost - effectiveness of varicella vaccination in Canada[J]. Vaccine, 2002, 20(7 - 8) : 1113 - 1125.
  • 7Scuffham P A, Lowin A V, Burgess M A. The cost - effectiveness of varicella vaccine programs for Australia[ J ]. Vaccine, 1999, 18 (5-6) :407 - 415.
  • 8Coudeville L, Paree F, Lebrun T, et al. The value of varicclla vaccination in healthy children: cost - benefit analysis of the situation in Franee[J]. Vaccine, 1999, 17(2):142 - 151.
  • 9Smith K J, Roberts M S. Cost - effectiveness of vaccination strategies in adults without a history of chickenpox [ J ] . Am J Med, 2000, 108(9) :723 - 729.
  • 10Gayman J .A cost - effectiveness model for analyzing two varicella vaccination strategies [ J ] . Am Health Syst Pharm, 1998, 55(24Suppl 4) : 4 - 8.

共引文献10

同被引文献15

  • 1刘晔,高嵩,赵军,王鹏,徐俊峰,李莉,徐秀凤,李占春,哈秀杰,李开军,刘延威,王丽华,宣黎波,王立成,王连成.冻干水痘减毒活疫苗免疫持久性观察[J].中国生物制品学杂志,2006,19(4):420-422. 被引量:10
  • 2Sauerbrei A, Zell R, Wutzler P. Analysis of repeat units in the R2 region among different Oka varicella-zoster virus vaccine strains and wild-type strains in Germany [ J ]. Intervirology, 2007,50( 1 ) : 40-44.
  • 3Galea SA, Sweet A, Beninger P, et al. The safety profile of varicelia vaccine:a 10-year review [J]. J Infect Dis, 2008, 197 (Suppl) 2:S165-S169.
  • 4Grose C. Varicella vaccination of children in the United States assessment after the first decade 1995-2005 [J]. J Clin Virol 2005,33(2) :89-95.
  • 5Takahashi M, Asano Y, Kamiya H, et al. Development of varicel la vaccine [J]. J Infect Dis,2008,197 (Suppl 2):S41-S44.
  • 6Gershon AA, Katz SL.Perspective on live varicella vaccine [J]. J Infect Dis, 2008, 197 (Suppl 2) :S242-S245.
  • 7Tillieux SL, Halsey WS, Thomas ES, et al. Complete DNA sequences of two oka strain varicella-zoster virus genomes [J]. J Virol, 2008, 82(22): 11023-11044.
  • 8Gomi Y, Imagawa T, Takahashi M, et al. Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity [J]. J Med Virol,2000,61 (4) :497-503.
  • 9Gomi Y , Sunamachi H, Mori Y, et al. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus [ J ]. J Virol, 2002,76 (22) : 11447-11459.
  • 10Gomi Y, Imagawa T, Takahashi M,et al. Comparison of DNA sequence and transactivation activity of open reading frame 62 of Oka varicella vaccine and its parental viruses [J]. Arch Virol Suppl,2001, (17) : 49-56.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部